The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

Cancer Cell

Volumn 29, Issue 4, 2016, Pages 574-586

  Townsend, Elizabeth C ^a   Murakami, Mark A ^a   Christodoulou, Alexandra ^a   Christie, Amanda L ^a   Köster, Johannes ^a   DeSouza, Tiffany A ^a   Morgan, Elizabeth A ^b   Kallgren, Scott P ^c   Liu, Huiyun ^a   Wu, Shuo Chieh ^a   Plana, Olivia ^a   Montero, Joan ^a   Stevenson, Kristen E ^a   Rao, Prakash ^a   Vadhi, Raga ^a   Andreeff, Michael ^o   Armand, Philippe ^a   Ballen, Karen K ^d   Barzaghi Rinaudo, Patrizia ^e,f   Cahill, Sarah ^a   Clark, Rachael A ^b   Cooke, Vesselina G ^e,f   Davids, Matthew S ^a   DeAngelo, Daniel J ^a   Dorfman, David M ^b   Eaton, Hilary ^a   Ebert, Benjamin L ^b   Etchin, Julia ^a   Firestone, Brant ^e,f   Fisher, David C ^a   Freedman, Arnold S ^a   Galinsky, Ilene A ^a   Gao, Hui ^e,f   Garcia, Jacqueline S ^a   Garnache Ottou, Francine ^g   Graubert, Timothy A ^d   Gutierrez, Alejandro ^a,h   Halilovic, Ensar ^e,f   Harris, Marian H ^h   Herbert, Zachary T ^a   Horwitz, Steven M ⁱ   Inghirami, Giorgio ^j   Intlekoffer, Andrew M ⁱ   Ito, Moriko ^e,f   Izraeli, Shai ^k   Jacobsen, Eric D ^a   Jacobson, Caron A ^a   Jeay, Sébastien ^e,f   Jeremias, Irmela ^l,m   Kelliher, Michelle A ⁿ   Koch, Raphael ^a   Konopleva, Marina ^o   Kopp, Nadja ^a   Kornblau, Steven M ^o   Kung, Andrew L ^p   Kupper, Thomas S ^b   LaBoeuf, Nicole ^b   LaCasce, Ann S ^a   Lees, Emma ^e,f   Li, Loretta S ^a   Look, A Thomas ^a   Murakami, Masato ^e,f   Muschen, Markus ^q   Neuberg, Donna ^a   Ng, Samuel Y ^a   Odejide, Oreofe O ^a   Orkin, Stuart H ^a   Paquette, Rachel R ^a   Place, Andrew E ^a   Roderick, Justine E ⁿ   Ryan, Jeremy A ^a   Sallan, Stephen E ^a   Shoji, Brent ^b   Silverman, Lewis B ^a   Soiffer, Robert J ^a   Steensma, David P ^a   Stegmaier, Kimberly ^a   Stone, Richard M ^a   Tamburini, Jerome ^r   Thorner, Aaron R ^a   van Hummelen, Paul ^a   Wadleigh, Martha ^a   Wiesmann, Marion ^e,f   Weng, Andrew P ^s   Wuerthner, Jens U ^e,f   Williams, David A ^p   Wollison, Bruce M ^a   Lane, Andrew A ^a   Letai, Anthony ^a   Bertagnolli, Monica M ^q   Ritz, Jerome ^a   Brown, Myles ^a   Long, Henry ^a   Aster, Jon C ^b   Shipp, Margaret A ^a   Griffin, James D ^a   Weinstock, David M ^a,t   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Plateforme de BioMonitoring   (France)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k TEL AVIV UNIVERSITY   (Israel)

^l INSTITUTE OF EPIDEMIOLOGY   (Germany)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r UNIVERSITÉ PARIS DESCARTES   (France)

^s BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^t BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE; MDM2 PROTEIN, HUMAN; NVP-CGM097; PIPERAZINE DERIVATIVE; PROTEIN MDM2; PROTEOME; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; MOUSE; NK T CELL LYMPHOMA; NONHUMAN; PATIENT DERIVED XENOGRAFT; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; T CELL LEUKEMIA; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL LINEAGE; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; INTERNET; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; LYMPHOMA; MALE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE BANK; TUMOR SUPPRESSOR GENE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINEAGE; FEMALE; GENE EXPRESSION PROFILING; GENES, P53; HETEROGRAFTS; HUMANS; INTERNET; ISOQUINOLINES; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; LYMPHOMA; MALE; MICE; MICE, INBRED NOD; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHENOTYPE; PIPERAZINES; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEOME; PROTO-ONCOGENE PROTEINS C-MDM2; RANDOM ALLOCATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TISSUE BANKS; TRANSCRIPTOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962740421     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.03.008     Document Type: Article

References (37)

1. Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013, 73:4372-4382.
2. Andreeff M., Kelly K.R., Yee K.W., Assouline S.E., Strair R., Popplewell L., Bowen D., Martinelli G., Drummond M.W., Vyas P., et al. Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia. Clin. Cancer Res. 2015, 22:868-876.
3. Aparicio S., Hidalgo M., Kung A.L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 2015, 15:311-316.
4. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
5. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Cora D., Di Nicolantonio F., Buscarino M., Petti C., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
6. Couzin-Frankel J. The littlest patient. Science 2014, 346:24-27.
7. Daniel V.C., Marchionni L., Hierman J.S., Rhodes J.T., Devereux W.L., Rudin C.M., Yung R., Parmigiani G., Dorsch M., Peacock C.D., et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009, 69:3364-3373.
8. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., Becker M., Merk J. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 2008, 14:6456-6468.
9. Gao H., Korn J.M., Ferretti S., Monahan J.E., Wang Y., Singh M., Zhang C., Schnell C., Yang G., Zhang Y., et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 2015, 21:1318-1325.
10. Gillet J.P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. USA 2011, 108:18708-18713.
11. Hausser H.J., Brenner R.E. Phenotypic instability of Saos-2 cells in long-term culture. Biochem. Biophys. Res. Commun. 2005, 333:216-222.
12. Hidalgo M., Amant F., Biankin A.V., Budinska E., Byrne A.T., Caldas C., Clarke R.B., de Jong S., Jonkers J., Maelandsmo G.M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014, 4:998-1013.
13. Jaffe E.S., Harris N.L., Stein H., Isaacson P.G. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008, 112:4384-4399.
14. Jeay S., Gaulis S., Ferretti S., Bitter H., Ito M., Valat T., Murakami M., Ruetz S., Guthy D.A., Rynn C., et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. Elife 2015, 4. 10.7554/eLife.06498.
15. Julien S., Merino-Trigo A., Lacroix L., Pocard M., Goere D., Mariani P., Landron S., Bigot L., Nemati F., Dartigues P., et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 2012, 18:5314-5328.
16. Klco J.M., Spencer D.H., Miller C.A., Griffith M., Lamprecht T.L., O'Laughlin M., Fronick C., Magrini V., Demeter R.T., Fulton R.S., et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 2014, 25:379-392.
17. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
18. Koster J., Rahmann S. Snakemake-a scalable bioinformatics workflow engine. Bioinformatics 2012, 28:2520-2522.
19. Ledford H. Translational research: 4 ways to fix the clinical trial. Nature 2011, 477:526-528.
20. Leek J.T., Storey J.D. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007, 3:1724-1735.
21. Liem N.L., Papa R.A., Milross C.G., Schmid M.A., Tajbakhsh M., Choi S., Ramirez C.D., Rice A.M., Haber M., Norris M.D., et al. Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 2004, 103:3905-3914.
22. Lv P.C., Sun J., Zhu H.L. Recent advances of p53-MDM2 small molecule inhibitors (2011-present). Curr. Med. Chem. 2015, 22:618-626.
23. Mak I.W., Evaniew N., Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 2014, 6:114-118.
24. Montero J., Sarosiek K.A., DeAngelo J.D., Maertens O., Ryan J., Ercan D., Piao H., Horowitz N.S., Berkowitz R.S., Matulonis U., et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015, 160:977-989.
25. Odejide O., Weigert O., Lane A.A., Toscano D., Lunning M.A., Kopp N., Kim S., van Bodegom D., Bolla S., Schatz J.H., et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014, 123:1293-1296.
26. Ott C.J., Kopp N., Bird L., Paranal R.M., Qi J., Bowman T., Rodig S.J., Kung A.L., Bradner J.E., Weinstock D.M. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood 2012, 120:2843-2852.
27. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N. Engl. J. Med. 2004, 350:1535-1548.
28. Reyal F., Guyader C., Decraene C., Lucchesi C., Auger N., Assayag F., De Plater L., Gentien D., Poupon M.F., Cottu P., et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 2012, 14:R11.
29. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
30. Ritchie M.E., Phipson B., Wu D., Hu Y., Law C.W., Shi W., Smyth G.K. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015, 43:e47.
31. Shukla S.A., Rooney M.S., Rajasagi M., Tiao G., Dixon P.M., Lawrence M.S., Stevens J., Lane W.J., Dellagatta J.L., Steelman S., et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 2015, 33:1152-1158.
32. Tabe Y., Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr. Hematol. Malig. Rep. 2015, 10:96-103.
33. Weigert O., Lane A.A., Bird L., Kopp N., Chapuy B., van Bodegom D., Toms A.V., Marubayashi S., Christie A.L., McKeown M., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J. Exp. Med. 2012, 209:259-273.
34. Weisberg E., Halilovic E., Cooke V.G., Nonami A., Ren T., Sanda T., Simkin I., Yuan J., Antonakos B., Barys L., et al. Inhibition of wild-type p53-expressing AML by the novel small molecule HDM2 inhibitor CGM097. Mol. Cancer Ther. 2015, 14:2249-2259.
35. Westcott P.M., Halliwill K.D., To M.D., Rashid M., Rust A.G., Keane T.M., Delrosario R., Jen K.Y., Gurley K.E., Kemp C.J., et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature 2015, 517:489-492.
36. Zelenetz A.D., Gordon L.I., Wierda W.G., Abramson J.S., Advani R.H., Andreadis C.B., Bartlett N., Byrd J.C., Czuczman M.S., Fayad L.E., et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J. Natl. Compr. Canc. Netw. 2015, 13:326-362.
37. Zhang X., Claerhout S., Prat A., Dobrolecki L.E., Petrovic I., Lai Q., Landis M.D., Wiechmann L., Schiff R., Giuliano M., et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013, 73:4885-4897.